ELDERPHARM

Indarts Exports Private Limited has submitted to the Exchange vide its letter dated March 26,2012 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for release of 25000 shares.

Cholamandalam Investment and Finance Company Limited has submitted to the Exchange vide its letter dated March 22, 2012 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Indarts Exports Pvt. Ltd. has submitted to the Exchange vide its letter dated March 20, 2012 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Indarts Exports Pvt. Ltd. has submitted to the Exchange vide its letter dated March 15, 2012 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Elder Pharmaceuticals Limited has informed the Exchange that there was fluctuation in Company's share price on March 06, 2012 and March 07, 2012. There was an Income Tax Search u/s 132 of Income Tax Act, 1961 on various premises of the Company. However, the said search has hardly yielded anything against the Company.

Elder Pharmaceuticals Limited has submitted to the Exchange the Standalone and Consolidated Financial Results along with Limited Review Report for the period ended December 31,2011.

Elder Pharmaceuticals Limited has informed the Exchange that on February 07, 2012, the Company through its Dubai wholly owned subsidiary has increased the stake in Elder Biomeda AD, Bulgaria from existing 92.2% to 100%.

Indarts Exports Pvt. Ltd . has submitted to the Exchange a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Indarts Exoports Pvt. Ltd . has submitted to the Exchange a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Akshaya Holdings Pvt. Limited has submitted to the Exchange a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Semit Pharmaceuticals & Chemicals Pvt. Ltd. has submitted to the Exchange a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Elder Pharmaceuticals Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended September 30,2011.

Elder Pharmaceuticals Limited has informed the Exchange regarding the outcome of the Annual General Meeting of the shareholders of the Company held on September 26, 2011.

Elder Pharmaceuticals Limited has informed the Exchange that at the meeting of the Board of Directors held on August 12, 2011, following decisions were taken: (1) To hold the Annual General Meeting of the Company on September 26, 2011. (2) To keep the transfer books closed from September 17, 2011 to September 26, 2011 (both days inclusive) for payment of dividend .

Elder Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on August 12, 2011 have recommended dividend @ 30% i.e. Rs. 3/- per share of Rs. 10/- each.

Elder Pharmaceuticals Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended June 30,2011.

Elder Pharmaceuticals Limited has submitted to the Exchange the Standalone Financial Results for the period ended March 31,2011.

Elder Pharmaceuticals Limited has informed the Exchange that the Company's Whole Time Director, Mr. Alok Saxena is giving an interview on the 'CNBC', TV channel with regards to the Company on June 07, 2011.

Elder Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 10, 2011 amongst others, the following decisions were taken: (1) To form a 50:50 Joint Venture in Guernsey for web marketing of VMS products manufactured by UK and European companies. (2) To approve the appointment of Mr. Madhav Joshi as President -Pharma of the Company.

Elder Pharmaceuticals Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended March 31,2011.

Elder Pharmaceuticals Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended December 31,2010.

Elder Pharmaceuticals Limited has informed the Exchange vide its letter dated January 03, 2011 regarding a press release, titled "Elder API Plant gets Japan Ministry of Health Accreditation".

Elder Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on December 23, 2010, has approved the allotment of fully paid 1188 of units of Rs. 10,00,000/- each under Secured Redeemable Non Convertible Debenture issue.

Elder Pharmaceuticals Limited has informed the Exchange that the scheme of arrangement has become effective from November 16, 2010 and accordingly acquisition of NutraHealth Plc, U.K. had been completed.

Elder Pharmaceuticals Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended September 30,2010.

Elder Pharmaceuticals Limited has informed the Exchange that the Court Convened Meeting was held on October 25, 2010 to approve the scheme of arrangement. The scheme was approved by requisite number of votes. The General Meeting of NeutraHealth plc was also held on October 25, 2010 to implement the scheme of arrangement. All the resolutions in order to approve and implement the Scheme received the requisite number of votes and were accordingly approved.

Elder Pharmaceuticals Limited has informed the Exchange that the Company holds a 61% stake in Elder Biomeda AD, Bulgaria through the Company's wholly owned subsidiary in Dubai. Kindly note that the stake has been increased to 92.2%.

Elder Pharmaceuticals Limited had informed the Exchange regarding the announcement made for the proposed takeover of an AIM listed Company in the U. K. by way of a Scheme of Arrangement. The Company has now informed the Exchange that the Scheme Document has been/is being posted on October 01, 2010 to the shareholders of the Target Company, viz NeutraHealth PLC.

Elder Pharmaceuticals Limited has informed the Exchange regarding the outcome of the Annual General Meeting of the shareholders of the Company held on September 28, 2010.

Elder Pharmaceuticals Limited has informed the Exchange that after the closure of the Qualified Institutions Placement issue on September 21, 2010, the Board of Directors of the Company, at their meeting held on September 24, 2010 have allotted 1,679,450 Equity Shares of Rs.10/- each of the Company for cash at an issue price of Rs.415/- including a premium of Rs.405/- per share.

Elder Pharmaceuticals Limited has informed the Exchange that the QIP Issue of the Company closed on September 21, 2010. The QIP Committee of the Company met on September 22, 2010 for noting the applications received by the Company/Book Running Lead Manager, viz. Karvy Investor Services Pvt. Ltd. Further, the Company has submitted to the Exchange a copy of resolution passed by the QIP Committee on September 22, 2010.

Elder Pharmaceuticals Limited has informed the Exchange that the Company has decided to make proposal to acquire a Company in the United Kingdom through its wholly owned subsidiary in Dubai, U.A.E by way of scheme of arrangement. The price offered by the Company is 6.5 pence per share for the issued and to be issued shares with an aggregate expected outlay of approximately GBP 9.80 million. A simultaneous announcement under Rule 2.5 of the U.K City Code on Mergers and Acquisitions has been made today i.e. on September 16, 2010 in London.

Elder Pharmaceuticals Limited has informed the Exchange that in the QIP Committee Meeting held on September 16, 2010, it was decided to open Qualified Institutions Placement (QIP) on September 17, 2010 and close it on September 21, 2010.

Elder Pharmaceuticals Limited has informed the Exchange that at the meeting of the Board of Directors held on August 18, 2010, following decisions were taken: (1) To hold the Annual General Meeting of the Company on September 28, 2010. (2) To keep the transfer books closed from September 20, 2010 to September 28, 2010 (both days inclusive) for the purpose of determining the eligible shareholders for divident payment.

Elder Pharmaceuticals Limited has submitted to the Exchange a brief summary of the comparative financial results for the year ended on March 31, 2008 and March 31, 2010.

Elder Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on August 18, 2010 have recommended for consideration of Shareholders declaration of dividend @ 30% i.e. Rs. 3/- per share.

Elder Pharmaceuticals Limited has informed the Exchange that the Board of Directors at their meeting held on July 27, 2010 have decided to accept the resignation of Mr. M.V. Thomas as Director with effect from July 01, 2010.

Elder Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on July 27, 2010 decided to accept the resignation of Mr. M. V. Thomas as Director with effect from July 01, 2010.

Elder Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 05, 2010, on recommendation of the Audit Committee appointed Mr. M V Thomas, Director (Finance) of the Company as CFO.

Elder Pharmaceuticals Limited has informed the Exchange that commercial activities have been commenced in Elder Bulgaria EOOD, the subsidiary of the step-down subsidiary of the Company in Bulgaria. Elder Bulgaria EOOD is engaged in distribution business in Bulgaria.

Elder Pharmaceuticals Limited has informed the Exchange with reference to the news item appearing in the business section of a newspaper dated February 11, 2010 under the title "Elder Pharma Eyes Buyouts in Africa, Asia" that: "The news mentioned under the title is baseless and Mr. Alok Saxena did not speak to anybody on the contents mentioned under the above title".

Elder Pharmaceuticals Limited has informed the Exchange that the Company's new manufacturing facility at village - Charba, Langha Road, near Dehradun, Uttarakhand has commenced commercial production in its Liquid Orals facility. Further the Company has submitted a copy of press release on this regard dated February 10, 2010 titled "Elder Commences new manufacturing facility in Dehradun". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/cont

Elder Pharmaceuticals Limited has informed the Exchange regarding a press release wide its letter dated January 28, 2010 titled "Elder Pharma records fastest growth in domestic market". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ELDERPHARMA_PR_02022010.zip target=NEW> For more details click here.</a>

Elder Pharmaceuticals Limited has informed the Exchange with reference to the news items that has appeared in the newspaper on January 15, 2010 regarding the Company. The Company wants to clarify that "Our Company through its Dubai subsidiary had entered into a joint venture in Ghana. However, for the reasons mentioned therein the same has been terminated. Through the said Dubai subsidiary the Company has established a Company under the laws of Bulgaria in which it owns 61 % stake. The said step down subsidiary has acquired Biomeda group companies in Bulgaria which are wholly owned by it".

Elder Pharmaceuticals Limited has informed the Exchange regarding the outcome of Annual General Meeting of the shareholders of the company held on September 29, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Elder_out_01102009.zip target=NEW> For more details click here.</a>

Elder Pharmaceuticals Limited has submitted to the Exchange a brief summary of the comparative financial results for the year ended on March 31, 2008 and March 31, 2009. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ELDER_UPDATES_25082009.zip target=NEW> For more details click here.</a>

Elder Pharmaceuticals Limited has informed the Exchange that the following decisions were taken at the Board Meeting held on the August 25, 2009 : 1) To recommend for consideration of Shareholders declaration of dividend @25% i.e. Rs. 2.50 per share. 2) To hold the Annual General Meeting of the Company on the September 29, 2009. 3) To keep transfer books closed from September 22, 2009 to September 29, 2009 (both days inclusive) for the purpose of determining the eligible shareholders for dividend payment.

Elder Pharmaceuticals Limited has informed the Exchange that "During the Board Meeting held on 29th April 2009, the resignation of Mr. Peter Bibby, who had submitted his resignation on health grounds, was placed before the Board and the same was accepted by the Board. During the same meeting the Board appointed Mrs. Urvashi Saxena as an Additional Director who shall be an Independent Director on the Board. Also, in the same meeting the Board, subject to the approval of the general meeting and the government and other regulatory bodies, if any, decided to re-appoint Mr. Jagdish Saxena as Managi

Elder Pharmaceuticals Limited had informed the Exchange about the unsolicited approach made by wholly owned subsidiary of the Company to NeutraHealth plc, UK for the possible partial offer at an indicative offer price of 5.5p per share which could result in the subsidiary's shareholding increasing from existing 21% to between 50 and 60%. The Company has now informed the Exchange that the said offer has since been terminated.

Elder Pharmaceuticals Limited has informed the Exchange that "The Wholly owned Dubai subsidiary of the Company has made an unsolicited approach NeutraHealth Plc, UK, in which it has 21% stake. The approach may or may not lead to a partial offer that would result in the subsidiary�s shareholding increasing from 21% to between 50 and 60%. The indicative partial offer price is at or around 5.5p per share".